未成熟血小板分数对化疗患者输注血小板的预测作用

Abstract
Figure/Table
References (0)
Related Citation (1)

Download: PDF (1492 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate whether immature platelet fraction (IPF%) predicate imminent platelet recovery after chemotherapy for the cancer patients, so that unnecessary platelet transfusion can be avoided. Methods: A total of 186 patients were enrolled and divided into blood transfusion group and non-transfusion group. IPF% of anticoagulated blood with EDTA-K2 was evaluated by means of the IPF master program equipped with SYSMEX XE-5000. The differences between IPF% and PLT of blood transfusion group were analyzed dynamically. The ROC curve was performed to evaluate the effect of those indictors in predicting whether PLT transfusion was needed. Results: The IPF% in the blood transfusion group [5.10% (2.48%, 10.68%)] was higher than that in the non-transfusion group [1.85% (1.20%, 3.50%)], and the blood platelet count in the blood transfusion group [35.00×109/L (12.75×109/L, 123.75×109/L)] was lower than in the non-transfusion group [150.50×109/L(94.75×109/L, 209.00×109/L)] (P<0.05). There was an increase of IPF% during PLT nadir. The results of ROC analysis demonstrated that there was no statistical difference between the AUC of PLT and IPF%. Conclusion: Increased IPF% indicates PLT destruction in peripheral blood, but IPF% measurement lacks the predictive power regarding imminent PLT recovery in cancer patients. Therefore decisions regarding prophylactic PC transfusions should not be based on this parameter.

Key words： immature platelet fraction platelet transfusion chemotherapy

Received: 01 August 2018

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUO Jingjing
	SHEN Wencai
	YE Xuanmei
	PAN Suzhen
	ZHOU Lianlian
	JIANG Minghua.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2018/V48/I12/925

[1] JUNG H, JEON H K, KIM H J, et al. Immature platelet fraction: establishment of a reference interval and diagnostic measure for thrombocytopenia[J]. Korean J Lab Med, 2010, 30(5): 451-459.
[2] 吕明恩, 李洋, 薛峰, 等. 应用未成熟血小板比例、未成熟血小板绝对值和血栓弹力图评估原发免疫性血小板减少症患者的出血风险[J]. 中华血液学杂志, 2015, 36(9): 759-764.
[3] STANWORTH S J, ESTCOURT L J, POWTER G, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers[J]. N Engl J Med, 2013, 368(19): 1771-1780.
[4] YAMAOKA G, KUBOTA Y, NOMURA T, et al. The immature platelet fraction is a useful marker for predicting the timing of platelet recovery in patients with cancer after chemotherapy and hematopoietic stem cell transplantation[J]. Int J Lab Hematol, 2010, 32(6 Pt 1): e208-216.
[5] NOMURA T, KUBOTA Y, KITANAKA A, et al. Immature platelet fraction measurement in patients with chronic liver disease: a convenient marker for evaluating cirrhotic change [J]. Int J Lab Hematol, 2010, 32(3): 299-306.
[6] NAHIRNIAK S, SLICHTER S J, TANAEL S, et al. Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia[J]. Transfus Med Rev, 2015, 29(1): 3-13.
[7] JAING T H, CHEN S H, WEN Y C, et al. Assessment of platelet activation and immature platelet fraction as predictors of platelet engraftment after hematopoietic stem cell transplantation[J]. Cell Transplant, 2016, 25(7): 1259-1264.
[8] VAN DER LINDEN N, KLINKENBERG L J, MEEX S J,
et al. Immature platelet fraction measured on the Sysmex XN hemocytometer predicts thrombopoietic recovery after autologous stem cell transplantation[J]. Eur J Haematol, 2014, 93(2): 150-156.
[9] RUISI M M, PSAILA B, WARD M J, et al. Stability of measurement of the immature platelet fraction[J]. Am J Hematol, 2010, 85(8): 622-624.
[10] PONS I, MONTEAGUDO M, LUCCHETTI G, et al. Correlation between immature platelet fraction and reticulated platelets. Usefulness in the etiology diagnosis of thrombocy-topenia[J]. Eur J Haematol, 2010, 85(2): 158-163.
[11] STRAUSS G, VOLLERT C, VON STACKELBERG A, et al.
Immature platelet count: a simple parameter for distinguishing thrombocytopenia in pediatric acute lymphocytic leukemia from immune thrombocytopenia[J]. Pediatr Blood Cancer, 2011, 57(4): 641-647.
[12] PREUSSER M, ELANDT K, SCHWARZINGER I, et al. Immature and absolute platelet count changes and thrombocytopenia in malignant glioma[J]. Eur J Clin Invest, 2011, 41(5): 539-545.
[13] 蒋伟燕, 江明华, 吴义忠, 等. 未成熟血小板分数在血小板减少性疾病中的变化[J]. 检验医学, 2013, 28(1): 47-50.
[14] MEINTKER L, FRITSCH J D, RINGWALD J, et al. Immature platelets do not reliably predict platelet recovery in patients with intensive chemotherapy or stem cell transplanta-tion[J]. Vox Sang, 2017, 112(2): 132-139.
[15] CYBULSKA A, MEINTKER L, RINGWALD J, et al. Measurements of immature platelets with haematology analysers are of limited value to separate immune thrombocytopenia from bone marrow failure[J]. Br J Haematol, 2017, 177(4): 612-619.